pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
admilparant · news · pharmadog
← back to admilparant
News mentioning admilparant
15
stories
9d
BMS R&D head to depart amid restructure
biospace
23d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
Oct 13, 26
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
biospace
Oct 12, 26
Bristol Myers dips on ‘confounding’ lung drug results
biopharma dive
Oct 12, 26
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
Oct 12, 26
Bristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugs
endpoints
Oct 12, 26
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Oct 1, 26
BMS reports liver injury events in lung disease program, with key readout near
biospace
Oct 1, 26
Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken
fiercebiotech
Sep 30, 26
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
biopharma dive
Sep 15, 26
J&J’s Contineum-partnered depression drug flunks another phase 2 test
fiercebiotech
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Jul 30, 26
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech